4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
- 13 July 2010
- journal article
- research article
- Published by Elsevier
- Vol. 18 (1) , 39-51
- https://doi.org/10.1016/j.ccr.2010.05.023
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivoCancer Biology & Therapy, 2010
- Genetic inactivation of AKT1 , AKT2 , and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulationProceedings of the National Academy of Sciences, 2010
- In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer ModelsClinical Cancer Research, 2009
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant CancersCancer Research, 2009
- Tumours with PI3K activation are resistant to dietary restrictionNature, 2009
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1Journal of Biological Chemistry, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901Bioorganic & Medicinal Chemistry Letters, 2008
- Ras, PI(3)K and mTOR signalling controls tumour cell growthNature, 2006
- The Extracellular Signal-regulated Kinase Pathway Regulates the Phosphorylation of 4E-BP1 at Multiple SitesJournal of Biological Chemistry, 2002